Search Results
Jul 28, 2026, 22:27 ET WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
please visit: www.wuxibiologics.com.*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)*The winner of the "2026 Best Contract Development & Manufacturing Organization
More news about: WuXi Biologics
Jul 28, 2026, 10:37 ET Cellipont Bioservices Celebrates Release of 100th GMP Batch
Cell therapy CDMO reaches major manufacturing milestone approximately one year after initiating GMP operations at its Texas facilityTHE WOODLANDS, Texas, July 28, 2026 /PRNewswire/ --
More news about: Cellipont Bioservices
Jul 27, 2026, 12:00 ET USA Cell Therapy Manufacturing Market Highlights Lonza Group as Global Market Reaches USD 23.2 Billion by 2036 at 14.1% CAGR | Future Market Insights
projected to be the fastest-growing market, registering a 17.2% CAGR, driven by expanding biopharmaceutical manufacturing capabilities, increasing CDMO activity, and favorable government support for biotechnology.Japan is expected to record a 16.4% CAGR, supported by accelerated
More news about: Future Market Insights
Jul 27, 2026, 09:00 ET AsymBio Kicks Off Construction of Fengxian R&D Building to Establish a Full-Lifecycle, One-Stop Biologics Service Ecosystem
Asymchem Group (stock codes: 002821.SZ / 6821.HK), focuses exclusively on biopharmaceutical CDMO services. Backed by Asymchem Group's 30 years of experience and global operations, AsymBio delivers one-stop CDMO services from early-stage and process development to toxicology, clinical, and commercial-scale
More news about: AsymBio
Jul 24, 2026, 18:37 ET Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
2026, and the Company is targeting premium pricing with expected gross margins in the range of 60% to 80%. Samsung's recently announced purchase of CDMO PolyPeptide Group AG for US$1.8 billion to gain manufacturing capacity is, in the Company's view, a positive indication that Vector is strategically
More news about: Vector Sciences & Therapeutics
Jul 24, 2026, 10:30 ET Asymchem's Dunhua 2 Carbapenem Manufacturing Site Successfully Completes its First FDA Inspection for Continuous Manufacturing of an API
July 24, 2026 /PRNewswire/ -- Asymchem, a leading global contract development and manufacturing organization (CDMO), announced that its dedicated carbapenem API manufacturing facility (Jilin Asymchem Pharmaceuticals Co. Ltd., also known as "DH2") successfully completed
More news about: Asymchem Laboratories
Jul 23, 2026, 12:00 ET Apertura Gene Therapy Named to Consortium Receiving Funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE Program to Develop Gene Therapies for Rare Childhood Diseases
Institute.Manufacturing support for the consortium will be provided by Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies. "Viralgen has extensive experience working with partners to manufacture AAV
More news about: Apertura Gene Therapy
Jul 23, 2026, 10:30 ET Single-use Bioreactors Market worth $9.58 billion by 2031 - Exclusive Report by MarketsandMarkets™
North America held the largest market share, supported by its established biopharmaceutical industry, substantial biologics R&D activity, mature CDMO ecosystem, and early adoption of disposable manufacturing technologies. The US remained the major contributor owing to its extensive pipelines for monoclonal
More news about: MarketsandMarkets
Jul 23, 2026, 05:00 ET FAMAR appoints Bruce Vielle as Chief Executive Officer
Greece, July 23, 2026 /PRNewswire/ -- FAMAR, a leading European contract development and manufacturing organisation (CDMO), today announced the appointment of Bruce Vielle as Chief Executive Officer, effective 3 August 2026. He succeeds Dr Riku Rautsola, who has led the
More news about: FAMAR Group
Jul 22, 2026, 19:03 ET Samsung Biologics Reports Second Quarter 2026 Financial Results
July 23, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the second quarter of fiscal year 2026.
More news about: Samsung Biologics
Jul 22, 2026, 07:45 ET Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
toward international government procurement.Manufacturing Capacity Supports Government Preparedness Programs — Valion Bio's wholly owned CDMO, Velocity Bioworks, has demonstrated manufacturing capacity equivalent to approximately 1.3 million doses of Entolimod, positioning the Company to support
More news about: Valion Bio, Inc.
Jul 21, 2026, 22:09 ET BIO Asia-Taiwan 2026 Unites 60 Countries, Showcasing Taiwan as a Global Biotech Innovation Partner
Partnering also surpassed 10,000 scheduled meetings, underscoring the event's role as a gateway for global companies seeking R&D collaborations, CDMO contracts, investment opportunities, and licensing partnerships in Asia.This year's exhibition brought together 16 national pavilions, while
More news about: Taiwan Bio Industry Organization
Jul 21, 2026, 08:33 ET DCN Dx Names Trevor Brown Chief Revenue Officer
has done one thing: help companies bring diagnostic tests to commercial success. Today, the company runs three specialized businesses. Its immunoassay CDMO has completed more than 560 programs and is the industry's go-to for developing and manufacturing rapid point-of-use tests, from early feasibility through
More news about: DCN Dx
Jul 21, 2026, 08:13 ET Wheeler Bio Appoints Rajesh Beri, Ph.D., as Chief Development Officer
July 21, 2026 /PRNewswire/ -- Wheeler Bio, Inc., a biologics contract development and manufacturing organization (CDMO), today announced the appointment of Rajesh Beri, Ph.D., as Chief Development Officer. The appointment of Dr. Beri is the latest in a series of steps
More news about: Wheeler Bio, Inc.
Jul 21, 2026, 03:35 ET Ecolab藝康參與 2026 亞洲生技大展，以污染控制、智慧清潔與病媒防護解決方案守護生技製程安全
在主展區生命科學領域，潔淨室污染控制以Klercide™ 無塵室清潔與消毒方案提供無菌酒精、生物殺滅劑、殺孢子劑與低殘留解決方案，可支援日常清潔、輪替消毒與無塵室污染控制需求；Bioquell® 生物去汙解決方案則採用過氧化氫燻蒸技術，適用於無塵室、隔離器、傳遞窗與關鍵環境的自動化生物去汙作業。聚焦 GMP 廠房污染控制，適用於藥業、CDMO 及受 GMP 規範的潔淨室空間。在醫療器械與臨床感染控制應用上，藝康亦展出針對內視鏡與精密手術器械再處理流程的完整解決方案，涵蓋器械清潔、浸泡消毒到乾燥儲存等關鍵環節。其中，MDG DRS 222 內視鏡乾燥儲存櫃針對醫療院所內視鏡中心設計，透過經驗證的乾燥程序與 HEPA
More news about: 藝康台灣
Jul 20, 2026, 13:28 ET World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
wholly-owned subsidiary Velocity Bioworks®, based in San Antonio, Texas, is a microbial fermentation contract development and manufacturing organization (CDMO). For additional information, please visit
More news about: Valion Bio, Inc.
Jul 19, 2026, 18:43 ET Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
PolyPeptide Group AG ("PolyPeptide") (ISIN CH1110760852, ticker symbol: PPGN), a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).
More news about: Samsung Biologics
Jul 17, 2026, 00:06 ET 啟新生技依循PIC/S GMP規範 打造細胞治療原物料與製造平台，瞄準日本、新加坡市場
GMP轉換、技術移轉、無菌充填及品質檢測，協助客戶加速從研發走向臨床應用。配合亞洲生技大展帶動的國際交流，啟新於7月14日接待僑務委員會主辦的「2026年臺灣生物科技產業參訪團」。21位來自四大洲、10個國家的僑臺商與企業主，實地走訪細胞培養基生產線與產品展示空間，了解啟新在再生醫療關鍵原料、細胞培養、製程開發及品質檢測的服務量能。團員背景涵蓋全球藥廠、CDMO、基因工程及生醫投資等領域，包括全球RNAi療法領導廠商Alnylam的CMC產品開發主管，以及英國阿斯特捷利康（AstraZeneca）全球法規事務總監等企業代表。啟新2025年底已與新加坡ESCO簽署合作協議，逐步建立東南亞市場合作基礎，未來將持續拓展
More news about: 啟新生物科技
Jul 14, 2026, 20:00 ET Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet
More news about: Insilico Medicine
Jul 14, 2026, 07:45 ET Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
timing and supply-chain readiness while creating the potential to support future government procurement, internal development programs and third-party CDMO services.Oncology expansion: The biological activity of the TLR5 platform may support development opportunities beyond biodefense, including
More news about: Valion Bio, Inc.
Jul 09, 2026, 03:31 ET WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
please visit: www.wuxibiologics.com.*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)*The winner of the "2026 Best Contract Development & Manufacturing Organization
More news about: WuXi Biologics
Jul 08, 2026, 10:00 ET Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced that its application for segmented production of antibody-drug conjugates (ADCs) at its Hangzhou site successfully passed a comprehensive
More news about: Altruist Biologics
Jul 08, 2026, 10:00 ET Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced that its application for segmented production of antibody-drug conjugates (ADCs) at its Hangzhou site successfully passed a comprehensive
More news about: Altruist Biologics
Jul 08, 2026, 09:38 ET Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton AdvancedPorton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has dual-headquarters in Cranbury, New Jersey, and Suzhou, China, providing end-to-end CDMO solutions for ATMPs including plasmids, viral vectors, cell therapy and nucleic acid
More news about: Porton Advanced
Jul 08, 2026, 09:22 ET Cambrex、Snapdragon Chemistry 及 Q1 Scientific 憑藉製藥業創新與可持續發展成果獲肯定
新澤西州東拉瑟福德2026年7月8日 /美通社/ -- 全球領先的合約開發及製造機構 (CDMO) Cambrex 欣然宣佈，旗下公司 Snapdragon Chemistry 與 NewAmsterdam Pharma 獲頒美國化學學會 2026 年綠色化學挑戰獎 (American Chemical Society's 2026 Green Chemistry Challenge Award)，以表彰其在藥物合成方面開發出更環保的合成途徑。
More news about: Cambrex